SDC2 and cancer: The identification of the syndecan-2 adhesion regulatory domain as a strong negative regulator of angiogenesis mean that both it and its binding partner CD148 are potential novel therapeutic targets in pathologies where angiogenesis is a feature, such as atherosclerosis, arthritis and cancer.